15 results on '"Siebenhofer, Andrea"'
Search Results
2. Long-term effects of weight-reducing drugs in people with hypertension
- Author
-
Siebenhofer, Andrea, additional, Winterholer, Sebastian, additional, Jeitler, Klaus, additional, Horvath, Karl, additional, Berghold, Andrea, additional, Krenn, Cornelia, additional, and Semlitsch, Thomas, additional more...
- Published
- 2021
- Full Text
- View/download PDF
Catalog
3. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus
- Author
-
Semlitsch, Thomas, additional, Engler, Jennifer, additional, Siebenhofer, Andrea, additional, Jeitler, Klaus, additional, Berghold, Andrea, additional, and Horvath, Karl, additional
- Published
- 2020
- Full Text
- View/download PDF
4. Management of overweight and obesity in primary care—A systematic overview of international evidence‐based guidelines
- Author
-
Semlitsch, Thomas, primary, Stigler, Florian L., additional, Jeitler, Klaus, additional, Horvath, Karl, additional, and Siebenhofer, Andrea, additional
- Published
- 2019
- Full Text
- View/download PDF
5. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus
- Author
-
Fullerton, Birgit, primary, Siebenhofer, Andrea, additional, Jeitler, Klaus, additional, Horvath, Karl, additional, Semlitsch, Thomas, additional, Berghold, Andrea, additional, and Gerlach, Ferdinand M, additional more...
- Published
- 2018
- Full Text
- View/download PDF
6. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus
- Author
-
Fullerton, Birgit, primary, Siebenhofer, Andrea, additional, Jeitler, Klaus, additional, Horvath, Karl, additional, Semlitsch, Thomas, additional, Berghold, Andrea, additional, Plank, Johannes, additional, Pieber, Thomas R, additional, and Gerlach, Ferdinand M, additional more...
- Published
- 2016
- Full Text
- View/download PDF
7. Long-term effects of weight-reducing diets in people with hypertension
- Author
-
Semlitsch, Thomas, primary, Jeitler, Klaus, additional, Berghold, Andrea, additional, Horvath, Karl, additional, Posch, Nicole, additional, Poggenburg, Stephanie, additional, and Siebenhofer, Andrea, additional more...
- Published
- 2016
- Full Text
- View/download PDF
8. Laryngeal mask airway versus endotracheal tube for percutaneous dilatational tracheostomy in critically ill adult patients
- Author
-
Strametz, Reinhard, primary, Pachler, Christoph, additional, Kramer, Johanna F, additional, Byhahn, Christian, additional, Siebenhofer, Andrea, additional, and Weberschock, Tobias, additional
- Published
- 2014
- Full Text
- View/download PDF
9. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus
- Author
-
Fullerton, Birgit, primary, Jeitler, Klaus, additional, Seitz, Mirjam, additional, Horvath, Karl, additional, Berghold, Andrea, additional, and Siebenhofer, Andrea, additional
- Published
- 2014
- Full Text
- View/download PDF
10. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
- Author
-
Horvath, Karl, primary, Jeitler, Klaus, additional, Berghold, Andrea, additional, Ebrahim, Susanne H, additional, Gratzer, Thomas W, additional, Plank, Johannes, additional, Kaiser, Thomas, additional, Pieber, Thomas R, additional, and Siebenhofer, Andrea, additional more...
- Published
- 2007
- Full Text
- View/download PDF
11. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus
- Author
-
Siebenhofer, Andrea, primary, Plank, Johannes, additional, Berghold, Andrea, additional, Jeitler, Klaus, additional, Horvath, Karl, additional, Narath, Markus, additional, Gfrerer, Robert, additional, and Pieber, Thomas R, additional more...
- Published
- 2006
- Full Text
- View/download PDF
12. Long-term effects of weight-reducing drugs in people with hypertension.
- Author
-
Siebenhofer A, Jeitler K, Horvath K, Berghold A, Posch N, Meschik J, and Semlitsch T
- Subjects
- Adult, Anti-Obesity Agents therapeutic use, Appetite Depressants therapeutic use, Blood Pressure drug effects, Cyclobutanes adverse effects, Cyclobutanes therapeutic use, Diet, Reducing, Female, Fructose adverse effects, Fructose analogs & derivatives, Fructose therapeutic use, Humans, Hypertension mortality, Lactones adverse effects, Lactones therapeutic use, Male, Middle Aged, Orlistat, Phentermine adverse effects, Phentermine therapeutic use, Piperidines adverse effects, Piperidines therapeutic use, Pyrazoles adverse effects, Pyrazoles therapeutic use, Randomized Controlled Trials as Topic, Rimonabant, Safety-Based Drug Withdrawals, Time, Topiramate, Anti-Obesity Agents adverse effects, Appetite Depressants adverse effects, Hypertension drug therapy, Weight Loss
- Abstract
Background: All major guidelines on antihypertensive therapy recommend weight loss; anti-obesity drugs may be able to help in this respect., Primary Objectives: To assess the long-term effects of pharmacologically induced reduction in body weight in adults with essential hypertension on all-cause mortality, cardiovascular morbidity, and adverse events (including total serious adverse events, withdrawal due to adverse events, and total non-serious adverse events)., Secondary Objectives: To assess the long-term effects of pharmacologically induced reduction in body weight in adults with essential hypertension on change from baseline in systolic blood pressure, change from baseline in diastolic blood pressure, and body weight reduction., Search Methods: We obtained studies using computerised searches of the Cochrane Hypertension Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Ovid EMBASE, the clinical trials registry ClinicalTrials.gov, and from handsearches in reference lists and systematic reviews (status as of 13 April 2015)., Selection Criteria: Randomised controlled trials in hypertensive adults of at least 24 weeks' duration that compared long-term pharmacologic interventions for weight loss with placebo. , Data Collection and Analysis: Two review authors independently selected studies, assessed risk of bias, and extracted data. Where appropriate and in the absence of significant heterogeneity between studies (P > 0.1), we pooled studies using fixed-effect meta-analysis. When heterogeneity was present, we used the random-effects method and investigated the cause of heterogeneity., Main Results: After updating the literature search, which was extended to include four new weight-reducing drugs, we identified one additional study of phentermine/topiramate, bringing the total number of studies to nine that compare orlistat, sibutramine, or phentermine/topiramate to placebo and thus fulfil our inclusion criteria. We identified no relevant studies investigating rimonabant, liraglutide, lorcaserin, or naltrexone/bupropion. No study included mortality and cardiovascular morbidity as predefined outcomes. Incidence of gastrointestinal side effects was consistently higher in those participants treated with orlistat versus those treated with placebo. The most frequent side effects were dry mouth, constipation, and headache with sibutramine, and dry mouth and paresthaesia with phentermine/topiramate. In participants assigned to orlistat, sibutramine, or phentermine/topiramate body weight was reduced more effectively than in participants in the usual-care/placebo groups. Orlistat reduced systolic blood pressure as compared to placebo by -2.5 mm Hg (mean difference (MD); 95% confidence interval (CI): -4.0 to -0.9 mm Hg) and diastolic blood pressure by -1.9 mm Hg (MD; 95% CI: -3.0 to -0.9 mm Hg). Sibutramine increased diastolic blood pressure compared to placebo by +3.2 mm Hg (MD; 95% CI: +1.4 to +4.9 mm Hg). The one trial that investigated phentermine/topiramate suggested it lowered blood pressure., Authors' Conclusions: In people with elevated blood pressure, orlistat and sibutramine reduced body weight to a similar degree, while phentermine/topiramate reduced body weight to a greater extent. In the same trials, orlistat and phentermine/topiramate reduced blood pressure, while sibutramine increased it. We could include no trials investigating rimonabant, liraglutide, lorcaserin, or naltrexone/bupropion in people with elevated blood pressure. Long-term trials assessing the effect of orlistat, liraglutide, lorcaserin, phentermine/topiramate, or naltrexone/bupropion on mortality and morbidity are unavailable and needed. Rimonabant and sibutramine have been withdrawn from the market, after long-term trials on mortality and morbidity have confirmed concerns about the potential severe side effects of these two drugs. The European Medicines Agency refused marketing authorisation for phentermine/topiramate due to safety concerns, while the application for European marketing authorisation for lorcaserin was withdrawn by the manufacturer after the Committee for Medicinal Products for Human Use judged the overall benefit/risk balance to be negative. more...
- Published
- 2016
- Full Text
- View/download PDF
13. Long-term effects of weight-reducing drugs in hypertensive patients.
- Author
-
Siebenhofer A, Jeitler K, Horvath K, Berghold A, Siering U, and Semlitsch T
- Subjects
- Adult, Blood Pressure drug effects, Cyclobutanes adverse effects, Diet, Reducing, Female, Humans, Hypertension mortality, Lactones adverse effects, Male, Middle Aged, Orlistat, Piperidines adverse effects, Pyrazoles adverse effects, Randomized Controlled Trials as Topic, Rimonabant, Safety-Based Drug Withdrawals, Time, Anti-Obesity Agents adverse effects, Hypertension drug therapy, Weight Loss
- Abstract
Background: All major guidelines for antihypertensive therapy recommend weight loss; anti-obesity drugs might be a helpful option., Primary Objectives: To assess the long-term effects of pharmacologically induced reduction in body weight with orlistat, sibutramine or rimonabant on:- all cause mortality - cardiovascular morbidity - adverse events, Secondary Objectives: - changes in systolic and/or diastolic blood pressure - body weight reduction even though sibutramine and rimonabant have been withdrawn from the market., Search Methods: Studies were obtained from computerised searches of Ovid MEDLINE, EMBASE, CENTRAL and from hand searches in reference lists and systematic reviews (status as of 17(th) August, 2012)., Selection Criteria: Randomized controlled trials in adult hypertensive patients with a study duration of at least 24 weeks comparing pharmacologic interventions (orlistat, sibutramine, rimonabant) for weight loss with placebo., Data Collection and Analysis: Two authors independently assessed risk of bias and extracted data. Studies were pooled using fixed-effect meta-analysis in the absence of significant heterogeneity between studies (p>0.1). Otherwise, we used the random effects method and investigated the cause of heterogeneity., Main Results: After the updated literature search, the number of studies remained the same, with eight studies comparing orlistat or sibutramine to placebo fulfilling our inclusion criteria. No relevant studies investigating rimonabant for weight loss were identified. No study included mortality and cardiovascular morbidity as a pre-defined outcome. Incidence of gastrointestinal side effects was consistently higher in orlistat treated vs. placebo treated patients. Most frequent side effects with sibutramine were dry mouth, constipation and headache. Patients assigned to weight loss diets, orlistat or sibutramine reduced their body weight more effectively than patients in the usual care/placebo groups. Blood pressure reduction in patients treated with orlistat was for systolic blood pressure (SBP): weighted mean difference (WMD): -2.5 mm Hg; 95% CI, -4.0 to -0.9 mm Hg and for diastolic blood pressure (DBP): WMD -1.9 mm Hg; 95% CI, -3.0 to -0.9 mm Hg. Meta-analysis showed DBP increase under therapy with sibutramine: WMD +3.2 mm Hg; 95%CI +1.4 to +4.9 mm Hg., Authors' Conclusions: In patients with elevated blood pressure, orlistat and sibutramine reduced body weight to a similar degree. In the same trials, orlistat reduced blood pressure and sibutramine increased blood pressure. No trials investigating rimonabant in people with elevated blood pressure could be included. Long-term trials assessing the effect of orlistat, sibutramine and rimonabant on mortality and morbidity are lacking. Rimonabant and sibutramine have been withdrawn from the market for the time being. more...
- Published
- 2013
- Full Text
- View/download PDF
14. Long-term effects of weight-reducing diets in hypertensive patients.
- Author
-
Siebenhofer A, Jeitler K, Berghold A, Waltering A, Hemkens LG, Semlitsch T, Pachler C, Strametz R, and Horvath K
- Subjects
- Aged, Blood Pressure, Cardiovascular Diseases prevention & control, Humans, Hypertension mortality, Middle Aged, Randomized Controlled Trials as Topic, Weight Loss, Diet, Reducing adverse effects, Hypertension diet therapy
- Abstract
Background: All major guidelines for antihypertensive therapy recommend weight loss. Thus dietary interventions that aim to reduce body weight might be a useful intervention to reduce blood pressure and adverse cardiovascular events associated with hypertension., Objectives: Primary objectivesTo assess the long-term effects of weight-reducing diets in hypertensive patients on- all cause mortality - cardiovascular morbidity - adverse events (including total serious adverse events, withdrawal due to adverse events and total non-serious adverse events)Secondary objectivesTo assess the long-term effects of weight-reducing diets in hypertensive patients on- change from baseline in systolic blood pressure - change from baseline in diastolic blood pressure - body weight reduction, Search Strategy: Studies were obtained from computerised searches of Ovid MEDLINE, EMBASE, CENTRAL and from searches in reference lists and systematic reviews., Selection Criteria: Randomised controlled trials (RCT) in adult hypertensive patients were included if they had a study duration of at least 24 weeks and compared weight reducing dietary interventions to no dietary intervention in adult patients with primary hypertension., Data Collection and Analysis: Two authors independently assessed risk of bias and extracted data. Studies were pooled using fixed-effect meta-analysis. In case of moderate or larger heterogeneity as measured by Higgins I(2), a random effects model was used., Main Results: Eight studies involving a total of 2100 participants with high blood pressure and a mean age of 45 to 66 years met our inclusion criteria. Mean treatment duration was 6 to 36 months. No study included mortality as a pre-defined outcome. One RCT evaluated the effects of dietary weight loss on a combined endpoint, consisting of the necessity of reinstating antihypertensive therapy and severe cardiovascular complications. In this RCT weight reducing diet lowered the endpoint, hazard ratio 0.70 (95% confidence interval [CI], 0.57 to 0.87) compared to no diet. None of the studies evaluated adverse events as designated in our protocol. Blood pressure was reduced in patients assigned to weight loss diets as compared to controls: systolic blood pressure (SBP): weighted mean difference (WMD): -4.5 mm Hg; 95% CI, -7.2 to -1.8 mm Hg (3 of 8 studies included in analysis), and diastolic blood pressure (DBP): WMD -3.2 mm Hg; 95% CI, -4.8 to -1.5 mm Hg (3 of 8 studies included in analysis). Patients' body weight was also reduced in dietary weight loss groups as compared to controls, WMD of -4.0 kg (95% CI: -4.8 to -3.2) (5 of 8 studies included in analysis). Two studies used withdrawal of antihypertensive medication as their primary outcome. Even though this was not considered a relevant outcome for this review, the results of these studies strengthen the finding of reduction of blood pressure by dietary weight loss interventions., Authors' Conclusions: In patients with primary hypertension, weight loss diets reduced body weight and blood pressure, however the magnitude of the effects are uncertain as a result of the small number of patients and studies that could be included in the analyses. It is not known whether weight loss reduces mortality and morbidity. No useful information on adverse effects was reported in the relevant trials. more...
- Published
- 2011
- Full Text
- View/download PDF
15. Long-term effects of weight-reducing drugs in hypertensive patients.
- Author
-
Siebenhofer A, Horvath K, Jeitler K, Berghold A, Stich AK, Matyas E, Pignitter N, and Siering U
- Subjects
- Adult, Blood Pressure drug effects, Female, Humans, Hypertension mortality, Male, Middle Aged, Orlistat, Piperidines adverse effects, Pyrazoles adverse effects, Randomized Controlled Trials as Topic, Rimonabant, Time, Anti-Obesity Agents adverse effects, Cyclobutanes adverse effects, Hypertension drug therapy, Lactones adverse effects, Weight Loss
- Abstract
Background: All major guidelines for antihypertensive therapy recommend weight loss; anti-obesity drugs might be a helpful option., Primary Objectives: To assess the long-term effects of pharmacologically induced reduction in body weight with orlistat, sibutramine or rimonabant on:- all cause mortality - cardiovascular morbidity - adverse events, Secondary Objectives: - changes in systolic and/or diastolic blood pressure - body weight reduction, Search Strategy: Studies were obtained from computerised searches of Ovid MEDLINE, EMBASE, CENTRAL and from hand searches in reference lists and systematic reviews., Selection Criteria: Randomized controlled trials in adult hypertensive patients with a study duration of at least 24 weeks comparing pharmacologic interventions (orlistat, sibutramine, rimonabant) for weight loss with placebo., Data Collection and Analysis: Two authors independently assessed risk of bias and extracted data. Studies were pooled using fixed-effect meta-analysis in the absence of significant heterogeneity between studies (p>0.1). Otherwise, we used the random effects method and investigated the cause of heterogeneity., Main Results: Eight studies comparing orlistat or sibutramine to placebo fulfilled our inclusion criteria. No relevant studies investigating rimonabant for weight loss were identified. No study included mortality and cardiovascular morbidity as a pre-defined outcome. Incidence of gastrointestinal side effects was consistently higher in orlistat treated vs. placebo treated patients. Most frequent side effects with sibutramine were dry mouth, constipation and headache. Patients assigned to weight loss diets, orlistat or sibutramine reduced their body weight more effectively than patients in the usual care/placebo groups. Blood pressure reduction in patients treated with orlistat was for systolic blood pressure (SBP): weighted mean difference (WMD): -2.5 mm Hg; 95% CI, -4.0 to -0.9 mm Hg and for diastolic blood pressure (DBP): WMD -1.9 mm Hg; 95% CI, -3.0 to -0.9 mm Hg. Meta-analysis showed DBP increase under therapy with sibutramine: WMD +3.2 mm Hg; 95%CI +1.4 to +4.9 mm Hg., Authors' Conclusions: In patients with elevated blood pressure, orlistat and sibutramine reduced body weight to a similar degree. In the same trials, orlistat reduced blood pressure and sibutramine increased blood pressure. No trials investigating rimonabant in people with elevated blood pressure could be included. Long-term trials assessing the effect of orlistat, sibutramine and rimonabant on mortality and morbidity are needed. more...
- Published
- 2009
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.